LONDON, Feb. 24, 2004 (PRIMEZONE) -- Antisoma plc, the biopharmaceutical company specialising in the development of novel anti-cancer drugs, today announces the appointment of Dr Ursula Ney as Chief Operating Officer. Reporting to CEO Glyn Edwards, Dr Ney will oversee the company's established drug development programmes and its business development activities. She has also been appointed to the Board of Antisoma plc.
Dr Ney was previously CEO of Charterhouse Therapeutics Ltd. Prior to Charterhouse, she spent thirteen years at Celltech plc, one of Europe's largest biotechnology companies, where she was Director of Development from 1993 to 2001 and served on the plc board from 2000 to 2001. Her earlier career included R&D positions at Roche and Sandoz. Dr Ney has a BSc and a PhD in pharmacology and an MBA.
Glyn Edwards, Chief Executive Officer of Antisoma, commented "Ursula Ney's appointment is an important step in Antisoma's expansion. She brings world-class experience in all aspects of drug development gained in a range of biotech and pharma settings."
About Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. The Company fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Antisoma forms partnerships with pharmaceutical companies to bring its products to market. In November 2002, Antisoma formed a broad strategic alliance with Roche to develop and commercialise products from Antisoma's pipeline. Please visit www.antisoma.com for further information about Antisoma.
This information is provided by RNS
The company news service from the London Stock Exchange